Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

Jean Pierre F. Issa, Vazganush Gharibyan, Jorge Cortes, Jaroslav Jelinek, Gail Morris, Srdan Verstovsek, Moshe Talpaz, Guillermo Garcia-Manero, Hagop M. Kantarjian

Research output: Contribution to journalArticle

244 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate'. Together they form a unique fingerprint.

Medicine & Life Sciences